These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 10930481)

  • 1. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Nukui Y; Picozzi VJ; Traverso LW
    Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Picozzi VJ; Kozarek RA; Traverso LW
    Am J Surg; 2003 May; 185(5):476-80. PubMed ID: 12727570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
    Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.
    Yeo CJ; Abrams RA; Grochow LB; Sohn TA; Ord SE; Hruban RH; Zahurak ML; Dooley WC; Coleman J; Sauter PK; Pitt HA; Lillemoe KD; Cameron JL
    Ann Surg; 1997 May; 225(5):621-33; discussion 633-6. PubMed ID: 9193189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol.
    Rocha FG; Hashimoto Y; Traverso LW; Dorer R; Kozarek R; Helton WS; Picozzi VJ
    Ann Surg; 2016 Feb; 263(2):376-84. PubMed ID: 25775069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
    Thomas CR; Weiden PL; Traverso LW; Thompson T
    Am J Clin Oncol; 1997 Apr; 20(2):161-5. PubMed ID: 9124192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
    Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
    BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
    Regine WF; John WJ; McGrath P; Strodel WE; Mohiuddin M
    J Hepatobiliary Pancreat Surg; 2000; 7(1):53-7. PubMed ID: 10982592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
    Carducci MA; Abrams RA; Yeo CJ; Hruban RH; Zahurak ML; Cameron JL; Grochow LB
    Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):143-50. PubMed ID: 8641911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
    J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
    Picozzi VJ; Abrams RA; Decker PA; Traverso W; O'Reilly EM; Greeno E; Martin RC; Wilfong LS; Rothenberg ML; Posner MC; Pisters PW;
    Ann Oncol; 2011 Feb; 22(2):348-54. PubMed ID: 20670978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
    Spitz FR; Abbruzzese JL; Lee JE; Pisters PW; Lowy AM; Fenoglio CJ; Cleary KR; Janjan NA; Goswitz MS; Rich TA; Evans DB
    J Clin Oncol; 1997 Mar; 15(3):928-37. PubMed ID: 9060530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
    Pisters PW; Abbruzzese JL; Janjan NA; Cleary KR; Charnsangavej C; Goswitz MS; Rich TA; Raijman I; Wolff RA; Lenzi R; Lee JE; Evans DB
    J Clin Oncol; 1998 Dec; 16(12):3843-50. PubMed ID: 9850029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.